Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Indoles
  • Pyrroles
  • Salvage Therapy

abstract

  • Sunitinib did not demonstrate a meaningful single-agent objective response rate in colorectal cancer refractory to standard chemotherapy. However, the mechanisms of action and acceptable safety profile of sunitinib warrant further study in combination with standard regimens for metastatic colorectal cancer.

publication date

  • October 20, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.12.8637

PubMed ID

  • 17947727

Additional Document Info

start page

  • 4793

end page

  • 9

volume

  • 25

number

  • 30